Physician profile
Mark Rosen
NPI 1588101091
$31,690.23
in general payments reported to CMS, 2019-2025
46 companies · $2,638 in 2025
The $2,638 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2021: $16K · 2022: $3,258 · 2023: $6,267 · 2024: $3,892 · 2025: $2,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $1,872 · Education: $25.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,899.35 |
| Travel and Lodging | $1,871.69 |
| Education | $25.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $15,830.69 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $4,548.87 | 2021-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $3,222.34 | 2021-2025 | Delstrigo, Pifeltro, Gardasil 9 |
| Janssen Biotech, INC. | $1,140.74 | 2021-2023 | Symtuza, Prezcobix |
| Abbvie INC. | $923.42 | 2021-2025 | |
| Novo Nordisk INC | $645.95 | 2021-2024 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $467.94 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Napo Pharmaceuticals INC | $413.55 | 2021-2025 | Mytesi |
| Lilly USA, LLC | $395.80 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $394.04 | 2021-2025 | |
| Antares Pharma, INC. | $356.28 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Axsome Therapeutics, INC. | $281.51 | 2023-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $262.90 | 2021-2022 | |
| Janssen Products, LP | $234.46 | 2021-2023 | Symtuza |
| Takeda Pharmaceuticals U.S.A., INC. | $186.92 | 2021-2025 | Trintellix, Eohilia |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $165.75 | 2022-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $160.70 | 2021 | |
| Abbott Laboratories | $158.28 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.26 | 2021-2023 | Stiolto Respimat, Spiriva Respimat |
| Theratechnologies INC. | $130.88 | 2022-2024 | Trogarzo, Egrifta |
| Amarin Pharma, INC. | $129.05 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $122.91 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $119.53 | 2022 | |
| Glaxosmithkline, LLC. | $116.23 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Kowa Pharmaceuticals America, INC. | $114.23 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $112.21 | 2022 | |
| Clarus Therapeutics INC. | $111.11 | 2021 | |
| Amgen INC. | $105.51 | 2021-2025 | Otezla, Repatha, Repatha |
| Alk-Abello, INC | $75.77 | 2024-2025 | Ragwitek, Odactra, Grastek |
| Halozyme INC | $75.46 | 2023 | |
| Janssen Pharmaceuticals, INC | $72.74 | 2024-2025 | Spravato |
| Boston Scientific Corporation | $49.80 | 2024-2025 | Watchman Flx, Wavewriter Alpha Prime 16 |
| Seqirus USA INC | $49.33 | 2022-2025 | Fluad Quadrivalent, Flucelvax Quadrivalent, Fluad |
| Genentech USA, INC. | $48.96 | 2021 | |
| Indivior INC. | $47.11 | 2023-2024 | Sublocade |
| Agios Pharmaceuticals, INC. | $43.37 | 2022 | |
| Corcept Therapeutics | $32.85 | 2025 | Korlym |
| Cipher Pharmaceuticals US LLC | $32.27 | 2025 | Spinosad, Natroba |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.26 | 2025 | Caplyta |
| Verity Pharmaceuticals INC. | $24.15 | 2025 | Trelstar |
| Bayer Healthcare Pharmaceuticals INC. | $23.13 | 2022 | |
| Sanofi Pasteur INC. | $22.05 | 2023 | |
| Exact Sciences Corporation | $21.80 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $17.05 | 2022 | |
| Tolmar, INC. | $16.96 | 2024 | |
| Currax Pharmaceuticals LLC | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,973.03 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.